This study investigates metastatic pancreatic cancer. Participants will receive different treatments to evaluate their effects on the condition.
The study evaluates the safety and effectiveness of combining an investigational medication with chemotherapy treatments.
- Who can participate: Adults aged 18 to 75 with stage IV metastatic pancreatic cancer who have not received prior first-line treatment are eligible. Participants must have an ECOG performance status of 0 or 1 and a measurable lesion according to RECIST 1.1.
- Study details: Participants will receive either the investigational medication combined with chemotherapy or chemotherapy alone.